Download Files:
Products Details
Product Description
– BGB-8035 is an orally active, highly selective bruton’s tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research[1].
Web ID
– HY-149051
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H31N5O4
References
– [1]Yunhang Guo, et al. Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. J Med Chem. 2023 Mar 23;66(6):4025-4044.
CAS Number
– 2283349-24-4
Molecular Weight
– 453.53
SMILES
– C=CC(N1CCC(CC1)[C@@H]2CCNC3=C(C(C4=CC(OC)=C(C(OC)=C4)C)=NN32)C(N)=O)=O
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Btk
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
